BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29

• Drug Development

  Cyclacel Pharmaceuticals, Inc.’s Second-Generation CDK2/9 Inhibitor, CYC065, Is An Effective Inducer Of Cell Death In B-Cell Lymphoma And Synergizes With Bcl-2 Or BET Inhibitors

  April 18, 2016

   · 

  7 min read
• Drug Development

  Conatus Pharma Late Breaker Oral Presentation At EASL Details Phase II Liver Cirrhosis Trial Three-Month Data

  April 18, 2016

   · 

  7 min read
• FDA

  Chiasma Crashes on FDA Drug Rejection of Mycapssa

  April 18, 2016

   · 

  8 min read
• Drug Development

  Loxo Oncology TRK Inhibitor LOXO-101 Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers In AACR Phase 1 Update

  April 18, 2016

   · 

  8 min read
• Lone Star Bio

  Freshloc Technologies To Attend TSHP Annual Seminar And Launch New Product At Show!

  April 18, 2016

   · 

  2 min read
• Business

  Biogen CEO Takes a Pay Cut in 2015 But Stock Vested Still Puts Him at Top

  April 18, 2016

   · 

  1 min read
• Drug Development

  Kite Pharma Cancer Therapy Responses in Solid Tumors Continued in Small Trial, NCI Review Halts Patient Enrollment

  April 18, 2016

   · 

  2 min read
• Drug Development

  AbbVie’s New Hep C Regimen Shows High Cure Rates in Mid-Stage Trial

  April 18, 2016

   · 

  7 min read
• Drug Development

  FDA Designates Merck & Co.'s Keytruda a Breakthrough for Classical Hodgkin Lymphoma

  April 18, 2016

   · 

  14 min read
• Policy

  Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)

  Accelerated assessment may provide a reduced review timeline from 210 to 150 days once the marketing authorization application (MAA) is filed and validated, which Alnylam intends to file by year-end 2017.

  April 18, 2016

   · 

  3 min read